Pub. Date : 2020 Jan
PMID : 31591140
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | BACKGROUND: Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). | tipiracil | triosephosphate isomerase 1 | Homo sapiens |
| 2 | IMPLICATIONS FOR PRACTICE: Trifluridine plus tipiracil (FTD + TPI) and regorafenib (REG) prolong survival in refractory metastatic colorectal cancer (mCRC) but have different tolerability profiles. | tipiracil | triosephosphate isomerase 1 | Homo sapiens |